Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.63 -0.11 (-2.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)

Updated

Taysha Gene Therapies' Asset Writedowns and Impairment was $4.84 million in FY2024, up 354.3% from $1.07 million in FY2023.

Analysis

Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends

  • Per Business Quant data, Asset Writedowns and Impairment in earlier years was $1.07 million in FY2023 (-97.1%) and $36.42 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Taysha Gene Therapies 1.51 Bn 1.51 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 4.84 Mn
Dec 31, 2023 449,000.00
Sep 30, 2023 616,000.00
API Access

Taysha Gene Therapies Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=TSHA&period=max&api_key=YOUR_API_KEY